# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Arthur Ashe (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML013-SYN
- Date: 2026-01-12
- Fictional facility: St. Posthumous Health Center
- Fictional author: Vivian Tolliver, MD
- Calendar frame: modern shifted

## Subjective

The patient participates in this fictional visit for establishing primary care for HIV after a recent diagnosis with cerebral toxoplasmosis, and for coronary artery disease after two bypass operations. **S**

## Objective

HIV-1 viral load: 42 {copies}/mL (high); CD4 count: 156 /uL (low); White cell count: 4.2 10*3/uL; Hemoglobin: 13 g/dL (low); Platelets: 198 10*3/uL; Sodium: 139 mmol/L; Potassium: 4.9 mmol/L; Creatinine: 1.18 mg/dL; eGFR: 78 mL/min/1.73 m²; Glucose: 92 mg/dL; ALT: 30 U/L; Total cholesterol: 158 mg/dL; HDL cholesterol: 40 mg/dL; Triglycerides: 150 mg/dL (high); LDL cholesterol: 88 mg/dL; HbA1c: 5.4%; PHQ-9: 5; AUDIT-C: 1. All results are synthetic.

BP 118/74 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 72 kg; BMI 21 kg/m². All vital signs are synthetic.

## Assessment

Active problems: HIV infection, diagnosed about four months before intake with a CD4 count of 58 cells/uL and cerebral toxoplasmosis (an AIDS-defining illness); on antiretroviral therapy since; synthetic modern episode linked to the documented transfusion-acquired infection; Cerebral toxoplasmosis, single left-sided lesion with right-hand weakness, diagnosed by stereotactic biopsy; six weeks of acute treatment completed; weakness recovered; on maintenance therapy; Coronary artery disease after two bypass operations (quadruple, then double), no angina; synthetic modern episode linked to the documented 1979 and 1983 operations; Old myocardial infarction at age 36; Hyperlipidemia, on high-intensity statin. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Continued without change: Bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg, one tablet by mouth once daily; take two hours before or six hours after antacids, calcium, iron, or magnesium **S**
- Continued without change: Sulfamethoxazole 800 mg and trimethoprim 160 mg (double strength), one tablet by mouth twice daily **S**
- Continued without change: Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily **S**
- Continued without change: Atorvastatin 80 mg oral tablet, one tablet by mouth daily **S**
- Started: Ezetimibe 10 mg oral tablet, one tablet by mouth daily **S**
- Continued without change: Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if pain is not better 5 minutes after the first tablet **S**

## Plan

- Antiretroviral therapy with bictegravir, emtricitabine, and tenofovir alafenamide once daily, chosen for its high barrier to resistance and few interactions with his cardiac medicines; viral load and CD4 count every three months. Guideline: Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV (current online edition); Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel (2024); Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America (2020) **S**
- Infectious diseases consultation to co-manage HIV: the regimen and its interactions, opportunistic-infection prophylaxis, the monitoring schedule, and vaccines. Guideline: Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV (current online edition); Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV: Toxoplasma gondii encephalitis and Pneumocystis pneumonia sections (current online edition) **S**
- Toxoplasma maintenance therapy with trimethoprim-sulfamethoxazole double strength twice daily, which also prevents Pneumocystis pneumonia, until the CD4 count is above 200 for more than six months on suppressive therapy; blood count, potassium, and creatinine every three months while on it. Guideline: Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV: Toxoplasma gondii encephalitis and Pneumocystis pneumonia sections (current online edition) **S**
- Secondary prevention of coronary disease after two bypass operations: aspirin, high-intensity atorvastatin with ezetimibe added for an LDL goal below 55 mg/dL, blood pressure below 130/80, a heart-healthy diet, regular exercise, and a written chest-pain plan with sublingual nitroglycerin. Guideline: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and hyperlipidemia monographs (2026) **S**
- Vaccines for adults with HIV: pneumococcal, hepatitis B with an antibody check afterwards, the two-dose meningococcal ACWY series, recombinant zoster, and seasonal influenza and COVID-19, with no live vaccines while the CD4 count is below 200. Guideline: Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America (2020); Adult Immunization Schedule by Medical Condition and Other Indication (2026) **S**
- Person-first, confidential care: he decides who learns of his diagnosis; support with disclosure if and when he chooses, peer support, and depression screening with the PHQ-9 at intake and six months and the PHQ-2 at the preventive visit. Guideline: Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America (2020); Depression and Suicide Risk in Adults: Screening (2023); CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and hyperlipidemia monographs (2026) **S**
